



Food and Drug Administration
Rockville, MD 20857

November 15, 2005

FILE COPY

James A. Losey
Skadden, Arps, Slate, Meagher & Flom LLP
1440 New York Avenue NW
Washington, District of Columbia 2005-2111

Dear Mr. Losey:

Your petition, submitted on behalf of GlaxoSmithKline, requesting the Food and Drug Administration remove metered-dose inhalers (MDI) containing the single active moieties beclomethasone, fluticasone, and salmeterol, respectively, from the essential-use list of ozone-depleting substance, was received by this office on 11/15/2005. It was assigned docket number 2005P-0464/CP1 and it was filed on 11/15/2005. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Jennie C. Butler, Director
Division of Dockets Management
Office of Management Programs
Office of Management

2005P.0464

ACK 1